Polycythemia Vera vs Secondary Polycythemia: Key Differences
At a Glance
Polycythemia vera is a bone marrow disorder, usually linked to a JAK2 mutation, while secondary polycythemia is a response to low oxygen, medicines, or another condition. JAK2, EPO levels, blood counts, and sometimes a bone marrow biopsy help distinguish them.
When you hear “polycythemia,” it means your blood has too many red blood cells, making it thicker than normal. However, the reason your body is making those extra cells completely changes your diagnosis and treatment.
Before diving into the causes, doctors must first confirm that you truly have extra red blood cells—a condition called absolute erythrocytosis [1]. Sometimes, a high cell count on a blood test is actually relative erythrocytosis, which happens when you are dehydrated or taking diuretic medications. This means you just have less fluid in your blood, making the red cells look falsely concentrated [1].
Once true overproduction is confirmed, the core difference between the two main types comes down to the origin of the problem:
- Polycythemia vera (PV) is a primary bone marrow disorder—a chronic myeloproliferative blood disorder (often described as a slow-growing blood cancer) where your marrow produces too many cells regardless of what your body actually needs [2].
- Secondary polycythemia (also called secondary erythrocytosis) is a reaction. Your bone marrow is healthy, but it is responding to an external signal telling it to make more red blood cells [3].
What Causes the High Cell Count?
In Polycythemia Vera:
PV is caused by an acquired genetic mutation in the bone marrow cells—this means it is something that developed over your lifetime, not usually something you inherited or can pass on [2]. In over 95% of cases, this is a mutation in the JAK2 gene [2]. This mutation acts like a broken “on” switch, causing the bone marrow to continuously churn out red blood cells, and often white blood cells and platelets, even though the body has plenty of oxygen [2].
In Secondary Polycythemia:
Secondary polycythemia happens when the body is starved for oxygen, or when something is inappropriately triggering erythropoietin (EPO), the hormone that normally stimulates red blood cell production [3]. To compensate, the kidneys release higher amounts of EPO to signal the bone marrow to produce more oxygen-carrying red cells [3]. Common causes include:
- Hypoxia (low oxygen levels in tissues): Caused by severe sleep apnea, smoking (which exposes you to carbon monoxide), chronic lung or heart disease, or living at high altitudes [4][5].
- Medications: Certain drugs, like testosterone therapy or SGLT2 inhibitors (used for diabetes), can stimulate red blood cell production [6].
- Tumors or kidney disease: Rarely, certain cysts, benign tumors, or cancers (especially in the kidneys) can inappropriately produce EPO [6][3].
How the Doctor Tells Them Apart
Because both conditions look similar on a basic Complete Blood Count (CBC), doctors rely on specific tests and diagnostic criteria:
- JAK2 Mutation Test: This molecular test is crucial. A positive result strongly supports a diagnosis of PV [7]. However, a negative standard JAK2 test does not completely rule out PV, as a small percentage of people have rarer mutations (like JAK2 exon 12) [8].
- EPO Level Test: Because the body doesn’t need extra red blood cells in PV, it tries to turn off production, often resulting in a low or suppressed EPO level [9]. Conversely, a normal or elevated EPO level typically suggests secondary polycythemia [7][9]. Keep in mind that a normal EPO level can occasionally happen in PV, so this test is interpreted alongside other results [7].
- Other Cell Counts: PV often causes an overproduction of red cells, white cells, and platelets all at once—a condition called panmyelosis [2]. Secondary polycythemia usually only affects red blood cells [2].
- Bone Marrow Biopsy: If blood tests are inconclusive, a hematologist may recommend a biopsy. While not always required, looking directly at the bone marrow cells under a microscope helps confirm if the marrow is diseased (PV) or just reacting normally to high EPO levels [10].
Why the Difference Matters for Treatment
The distinction is critical because treating one condition like the other can be dangerous.
Treating Polycythemia Vera:
PV carries a high risk of thrombosis (blood clots), so treatment focuses on controlling cell production and lowering clot risk [11]. Standard care includes:
- Therapeutic Phlebotomy: Regularly removing blood to maintain a strict hematocrit (the percentage of your blood made up of red cells) below 45% [11].
- Low-Dose Aspirin: Often given to reduce the stickiness of platelets and lower the risk of heart attacks and strokes [11]. However, aspirin is not safe for everyone and is avoided if you have a high bleeding risk, history of ulcers, or allergies [12].
- Cytoreductive Therapy: These are medications (like hydroxyurea or interferon) that slow down the bone marrow’s production of blood cells [11]. They are not given to everyone; they are usually prescribed for patients at higher risk of clots, such as those over 60 or with a previous history of thrombosis [13].
Treating Secondary Polycythemia:
Secondary polycythemia is treated by fixing the underlying cause, not by suppressing the bone marrow [14].
- If sleep apnea is the cause, using a CPAP machine may help improve blood counts.
- If smoking or a medication (like testosterone) is responsible, your doctor may help you quit or adjust your prescription [15][16]. Never stop prescribed medications without consulting your doctor.
- Unlike PV, doctors usually avoid strict phlebotomy schedules in secondary polycythemia. If the body is making extra cells to compensate for low oxygen, routinely removing blood can worsen oxygen starvation [14][16]. Phlebotomy is only used in highly symptomatic or extreme secondary cases, under strict specialist supervision [16]. Cytoreductive therapies are also avoided [11].
When to Seek Immediate Care
Because high red blood cell counts increase your risk of blood clots, seek emergency medical help immediately if you experience symptoms of a clot, including: sudden chest pain, severe shortness of breath, a painful or swollen leg, sudden weakness or numbness on one side of your face or body, difficulty speaking, or sudden severe headache or vision changes. Also seek urgent care if you experience significant bleeding (such as vomiting blood or black stools), especially if you are taking aspirin.
Common questions in this guide
What is the main difference between polycythemia vera and secondary polycythemia?
How do doctors distinguish PV from secondary polycythemia?
What does a JAK2 or EPO result mean in polycythemia?
How is polycythemia vera treated differently from secondary polycythemia?
Can dehydration cause a high red blood cell count?
When should I seek emergency care with a high red blood cell count?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Does my bloodwork show true absolute erythrocytosis, or could this be relative erythrocytosis from something like dehydration?
- 2.What were the specific results of my EPO and JAK2 mutation tests, and do we need to test for rarer JAK2 variants?
- 3.Are my white blood cell and platelet counts also elevated, or is it just my red blood cells?
- 4.If this is secondary polycythemia, what tests are we doing to find the root cause, such as a sleep study or medication review?
- 5.Based on my medical history and risk factors, is taking low-dose aspirin safe and appropriate for me right now?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (16)
- 1
Erythrocytosis: Diagnosis and investigation.
Noumani I, Harrison CN, McMullin MF
International journal of laboratory hematology 2024; (46 Suppl 1()):55-62 doi:10.1111/ijlh.14298.
PMID: 38695361 - 2
Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
Rumi E, Cazzola M
Blood 2017; (129(6)):680-692 doi:10.1182/blood-2016-10-695957.
PMID: 28028026 - 3
JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and management.
Gangat N, Szuber N, Tefferi A
American journal of hematology 2023; (98(6)):965-981 doi:10.1002/ajh.26920.
PMID: 36966432 - 4
Increased blood reactive oxygen species and hepcidin in obstructive sleep apnea precludes expected erythrocytosis.
Song J, Sundar KM, Horvathova M, et al.
American journal of hematology 2023; (98(8)):1265-1276 doi:10.1002/ajh.26992.
PMID: 37350302 - 5
JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views.
Gangat N, Szuber N, Pardanani A, Tefferi A
Leukemia 2021; (35(8)):2166-2181 doi:10.1038/s41375-021-01290-6.
PMID: 34021251 - 6
Erythrocytosis and CKD: A Review.
Aoun M, Jadoul M, Anders HJ
American journal of kidney diseases : the official journal of the National Kidney Foundation 2024; (84(4)):495-506 doi:10.1053/j.ajkd.2024.02.015.
PMID: 38621632 - 7
Diagnostic Performance of Erythropoietin Levels in Polycythemia Vera: Experience at a Comprehensive Cancer Center.
Davila-Gonzalez D, Barrios-Ruiz A, Fountain E, et al.
Clinical lymphoma, myeloma & leukemia 2021; (21(4)):224-229 doi:10.1016/j.clml.2020.11.002.
PMID: 33349602 - 8
JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis.
Maddali M, Kulkarni UP, Ravindra N, et al.
Annals of hematology 2020; (99(5)):983-989 doi:10.1007/s00277-020-04004-7.
PMID: 32277273 - 9
The role of a low erythropoietin level for the polycythemia vera diagnosis.
Lupak O, Han X, Xie P, et al.
Blood cells, molecules & diseases 2020; (80()):102355 doi:10.1016/j.bcmd.2019.102355.
PMID: 31525610 - 10
Impact of World Health Organization (WHO) Revised Criteria-2016 on the Diagnosis of Polycythemia Vera.
Nathany S, Koulmane Laxminarayana SL, Tewari S, et al.
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2020; (36(3)):477-483 doi:10.1007/s12288-019-01202-w.
PMID: 32647421 - 11
Diagnosis and Treatment of Polycythemia Vera: A Review.
Tremblay D, Kremyanskaya M, Mascarenhas J, Hoffman R
JAMA 2025; (333(2)):153-160 doi:10.1001/jama.2024.20377.
PMID: 39556352 - 12
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A, Barbui T
American journal of hematology 2015; (90(2)):162-73 doi:10.1002/ajh.23895.
PMID: 25611051 - 13
Moving toward disease modification in polycythemia vera.
Bewersdorf JP, How J, Masarova L, et al.
Blood 2023; (142(22)):1859-1870 doi:10.1182/blood.2023021503.
PMID: 37729609 - 14
Polycythemia Vera: Rapid Evidence Review.
Fox S, Griffin L, Robinson Harris D
American family physician 2021; (103(11)):680-687.
PMID: 34060791 - 15
[Approach to the Patient with Polycythemia].
Leviatan I, Ellis M
Harefuah 2026; (165(7)):453-458.
PMID: 42557631 - 16
Successful use of phlebotomy to treat severe secondary polycythemia due to chronic lung disease.
Fuqua J, Reece J, Sofka S
Hematology reports 2021; (13(2)):8961 doi:10.4081/hr.2021.8961.
PMID: 34221292
This comparison is for educational purposes and does not replace medical advice. A hematologist or other clinician should interpret your blood counts, EPO and JAK2 results and select treatment for your situation.
Get notified when new evidence is published on Polycythemia vera.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.